Utility of serum protein-bound neutral hexoses and L-fucose for estimation of malignant tumor extension and evaluation of efficacy of therapy.
Summary The method used permits correction for the influence of the neutral hexoses, galactose and mannose, on the apparent concentration of protein-bound l-fucose, as estimated by the…
A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal.
Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
- M. Dolan, M. Mastri, A. Tracz, J. Christensen, G. Chatta, J. Ebos
- Biology, MedicinePLoS ONE
- 1 August 2019
Results suggest that the diverse and often inconsistent compensatory signaling mechanisms found to contribute to TKI resistance may paradoxically improve the tumor-inhibiting effects of broad-spectrum TKIs such as sitravatinib that are able to block multiple signaling pathways.
Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
These are the first studies to assess and compare “off-target” host secretory effects of VEGF and PD-1 pathway inhibition that occur independent of tumor stage or tumor response to therapy, and show that host TIS signatures differ between drug target, drug class, and dose.
Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model
The findings establish the feasibility of using short, MHC-I-restricted neoepitopes for straightforward immunization with multivalent or validated neoEPitopes to induce cytotoxic CD8+ T cells and could be useful for preclinical studies involving renal cell carcinoma immunotherapy.
Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells
It is shown that prolonged PD-L1 inhibition can ‘rewire’ existing intracellular IFN:PD-L 1 signaling crosstalk to drive secretory programs that help protect tumors from immune cell attack and represent a targetable vulnerability to overcome acquired resistance in patients.
Abstract 3986: Combination of tamoxifen and doxorubicin targets estrogen receptor beta-mutant p53-p73 axis: A novel therapeutic strategy for triple negative breast cancer
A novel ER beta-mutant p53-p73 axis that could be targeted by Tam in combination with chemotherapy is revealed, raising the possibility of repurposing Tam to treat molecularly stratified TNBC that expresses both ERβ and mutant p53.
Abstract 3195: Hijacked senescence secretomes as 'immune primers' of antiangiogenic TKI efficacy
Abstract 326: Enhanced efficacy of Sitravatinib (MGCD516) in metastatic models of antiangiogenic therapy resistance
These studies suggest that broad-spectrum RTKI inhibitors such as sitravatinib that target multiple metastasis-promoting mechanisms improve efficacy after antiangiogenic treatment failure and improve outcomes in a second-line setting.
Main Text 9.16.22ALLREF
1Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. 2Department of Biological Sciences, University at Buffalo, State University of New York, Buffalo, NY…